← Leaderboards
Lindsay H Burns
Cassava Sciences, Inc
$16,572,741
Attributed
$17,809,563
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4M · FY2015–21$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$17,809,563 · 7
By mechanism
R44$14,804,000 · 5
R01$2,710,220 · 1
R42$295,343 · 1
Top collaborators
- George Ben Thornton3 shared
- Hoau-Yan Wang3 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseasePreventFilaminClinical TrialsBindingAutopsyTau ProteinsAffinityAlpha-Bungarotoxin ReceptorSmall MoleculeInsulin ReceptorNeurofibrillary TanglesSignal TransductionNeuroinflammationAmyloidReceptorBrainScaffolding ProteinOralDoseMolecular ConformationPathologicPharmaceutical Preparations
Grant awards (16)
Food Effect study and drug supply scale-up for PTI-125$2,710,220
R01 · FY2021 · AG · contact PI
Open-label extension of a 3-month blinded clinical trial of PTI-125$2,499,896
R44 · FY2020 · AG · contact PI
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease$450,142
R44 · FY2020 · AG
Increasing size of Phase 2b clinical trial to 60 patients$374,500
R44 · FY2020 · AG · contact PI
Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate$2,896,561
R44 · FY2019 · AG · contact PI
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease$1,109,748
R44 · FY2019 · AG
Solid oral dosage form and chronic tox for PTI-125$2,896,320
R44 · FY2018 · AG · contact PI
Extending clinical trial in AD patients from 1 to 3 months$374,500
R44 · FY2018 · AG · contact PI
Additional costs related to formulation, chronic tox and general development of PTI-125$350,000
R44 · FY2018 · AG · contact PI
Multiple Ascending Dose clinical trial of PTI-125, a novel AD therapeutic candidate$260,585
R44 · FY2018 · AG · contact PI
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease$1,500,000
R44 · FY2017 · AG · contact PI
Development of PTI-125-DX, a blood-based diagnostic for Alzheimer's disease$295,343
R42 · FY2017 · AG
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease$225,000
R44 · FY2017 · AG · contact PI
Additional bioanalytical, dose analysis and DSMB costs for PTI-125 development$141,748
R44 · FY2017 · AG · contact PI
IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease$1,500,000
R44 · FY2016 · AG · contact PI
IND- and NDA-enabling toxicology studies for PTI-125, a novel small molecule for Alzheimer's disease$225,000
R44 · FY2015 · AG · contact PI